Score Overview
Explore the 2021 public Archive ranking →
Where Vertex Pharmaceuticals Inc has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- VRTX
1997: 97.4% · 2021: 2.5% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 527.67 | — |
1 Year2025-09-26 | $ 385.74 | 36.79% |
5 Years2021-09-28 | $ 181.60 | 190.57% |
10 Years2016-09-28 | $ 88.84 | 493.96% |
20 Years2006-09-28 | $ 33.39 | 15x |
30 Years1996-09-27 | $ 14.63 | 36x |
All Time1991-07-24 | $ 4.50 | 117x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1991-07-24 |
|---|---|---|---|---|---|---|---|
| Price | $ 527.67 | $ 385.74 | $ 181.60 | $ 88.84 | $ 33.39 | $ 14.63 | $ 4.50 |
| Return | — | 36.79% | 190.57% | 493.96% | 15x | 36x | 117x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 12.62B | $ 4.40B | $ 7.85B |
| 2025 | $ 12.07B | $ 3.95B | $ 6.61B |
| 2024 | $ 11.02B | -$ 535M | $ 6.11B |
| 2023 | $ 9.86B | $ 3.61B | $ 11.21B |
| 2022 | $ 8.93B | $ 3.32B | $ 10.77B |
| 2021 | $ 7.57B | $ 2.34B | $ 7.52B |
| 2020 | $ 6.20B | $ 2.71B | $ 6.65B |
| 2019 | $ 4.16B | $ 1.17B | $ 3.80B |
| 2018 | $ 3.04B | $ 2.09B | $ 3.16B |
| 2017 | $ 2.48B | $ 263M | $ 2.08B |
| 2016 | $ 1.70B | -$ 112M | $ 1.43B |
| 2015 | $ 1.03B | -$ 558M | $ 1.04B |
| 2014 | $ 580M | -$ 738M | $ 1.38B |
| 2013 | $ 1.21B | -$ 445M | $ 1.46B |
| 2012 | $ 1.52B | -$ 107M | $ 1.32B |
| 2011 | $ 1.41B | $ 29M | $ 968M |
| 2010 | $ 143M | -$ 754M | $ 1.03B |
| 2009 | $ 102M | -$ 641M | $ 1.28B |
| 2008 | $ 175M | -$ 459M | $ 832M |
| 2007 | $ 199M | -$ 391M | $ 460M |
| 2006 | $ 216M | -$ 206M | $ 704M |
| 2005 | $ 160M | -$ 203M | $ 361M |
| 2004 | $ 102M | -$ 166M | $ 386M |
| 2003 | $ 69M | -$ 196M | $ 583M |
| 2002 | $ 161M | -$ 108M | $ 634M |
| 2001 | $ 167M | -$ 66M | $ 743M |
| 2000 | $ 78M | -$ 39M | $ 459M |
| 1999 | $ 61M | -$ 41M | $ 187M |
| 1998 | $ 44M | -$ 33M | $ 24M |
| 1997 | $ 43M | -$ 19M | $ 71M |
| 1996 | $ 13M | -$ 40M | $ 34M |
| 1995 | $ 22M | -$ 21M | $ 28M |
| 1994 | $ 19M | -$ 17M | $ 71M |
| 1993 | $ 27M | $ 2M | $ 28M |
| 1992 | $ 3M | -$ 8M | $ 11M |
| IPO1991 | $ 3M | -$ 5M | $ 27M |
Vertex Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 6.20B to $ 12.07B and net income grew from $ 2.71B to $ 3.95B. Revenue increased in every one of those 5 years; net income in 4.
Between 2015 and 2025, revenue grew from $ 1.03B to $ 12.07B and net income went from -$ 558M to $ 3.95B. Revenue increased in every one of those 10 years; net income in 7.
Vertex Pharmaceuticals Inc currently holds a 20-year HDB Score of 6.5 out of 10. How the HDB Score is calculated.
Membership
Continue VRTX’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
